Specifically, leptin therapy improves glycemic control and decreases triglyceride levels, thus effectively improving the symptoms of NASH (Polyzos et al., 2019; Baykal et al., 2020) (Figure 3). The gene discussed is LEP; the disease is metabolic dysfunction-associated steatohepatitis.